Thyroid cancer, BRAF-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Unfilled
If you are interested in this role, please contact us at [email protected].

Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.

2 regimens on this page
2 variants on this page


Differentiated thyroid cancer, all lines of therapy

Vemurafenib monotherapy

Regimen

Study Years of enrollment Evidence
Brose et al. 2016 (NO25530) 2011-2013 Phase 2

Note: this study was in patients with papillary thyroid cancer, only.

Targeted therapy

Continued indefinitely

References

  1. NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01286753

Anaplastic thyroid cancer, all lines of therapy

Dabrafenib & Trametinib

Regimen

FDA-recommended dose
Study Years of enrollment Evidence Efficacy
Subbiah et al. 2017 (ROAR) 2014-2016 Phase 2, <20 pts in subgroup (RT) ORR: 63% (95% CI, 35-85)

Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.

Targeted therapy

Continued indefinitely

References

  1. ROAR: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02034110
    1. Update: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. link to original article PubMed